Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  1986-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0360-3016(86)90236-1PMID 3017904
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy.

  1985cited by this paper
• Hypoxic cell radiosensitizers: expectations and progress in drug development.

  1985cited by this paper
• Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.

  1984cited by this paper
• Clinical trials of radiosensitizers: what should we expect?

  1984cited by this paper
• The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.

  1984cited by this paper
• A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.

  1984cited by this paper
• Initial pharmacology and toxicology of intravenous desmethylmisonidazole.

  1982cited by this paper
• Clinical perspectives for the use of new hypoxic cell sensitizers.

  1982cited by this paper
• Radiation therapy oncology group clinical trials with misonidazole

  1981cited by this paper

• An Analysis of the Radiosensitiser Applications in the Biomedical Field.

  2024cites this paper
• Hypoxia-targeted drug delivery.

  2019cites this paper
• Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo.

  2012cites this paper
• KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics

  2008cites this paper
• New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.

  2008cites this paper
• Cellular uptake and radiosensitization of SR-2508 loaded PLGA nanoparticles

  2008cites this paper
• Radiosensitization by the combination of SR-2508 and paclitaxel in hypoxic human tumor cells in vitro.

  2007cites this paper
• Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.

  2007cites this paper
• Porphyrin‐ and Expanded Porphyrin‐Based Diagnostic and Therapeutic Agents

  2007cites this paper
• The Role of Tumor Hypoxia in Head and Neck Cancer Radiotherapy

  2005cites this paper
• A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.

  2003cites this paper
• A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy.

  2003cites this paper
• Sensitizers and protectors of radiation and chemotherapy.

  2001cites this paper
• The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

  1999cites this paper
• Concurrent chemoradiation in the treatment of head and neck cancer.

  1999cites this paper
• Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imagin

  1998cites this paper
• Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.

  1998cites this paper
• Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays.

  1998cites this paper
• Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime.

  1997cites this paper
• Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).

  1996cites this paper
• Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.

  1995cites this paper
• Electrode potentials for bioreductive agents from neural networks.

  1994cites this paper
• Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.

  1994cites this paper
• Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice.

  1994cites this paper
• Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer.

  1994cites this paper
• Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

  1993cites this paper
• Design of Novel Bioreductive Drugs

  1992cites this paper
• Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.

  1992cites this paper
• Pharmacokinetics of intratumoral RK-28, a new hypoxic radiosensitizer.

  1992cites this paper
• 4-Fluorobenzylamine and phenylalanine methyl ester conjugates of 2-nitroimidazole: evaluation as hypoxic cell radiosensitizers.

  1992cites this paper
• Pharmacology and clinical investigation of SR-2508 (etanidazole).

  1991cites this paper
• Radiation oncology: past achievements and ongoing controversies.

  1991cites this paper
• Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).

  1991cites this paper
• A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

  1991influential citation
• Therapeutic advantage of hypoxic cells in tumors: a theoretical study.

  1991cites this paper
• Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.

  1991cites this paper
• In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.

  1991cites this paper
• A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer.

  1991cites this paper
• Hypoxic Cell Sensitizers in the Management of Brain Tumours

  1991cites this paper
• Radiation and chemotherapy sensitizers and protectors.

  1990cites this paper
• Radiation therapy for squamous cell carcinomas of the oral cavity and oropharynx: a review of recent techniques.

  1990cites this paper
• Pharmacokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nervous tissue.

  1990cites this paper
• Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.

  1990cites this paper
• Radiation Oncology: Radiobiological and Physiological Perspectives

  1990cites this paper
• The emerging biology of modern radiation oncology.

  1990cites this paper
• Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).

  1990cites this paper
• Critical Appraisal of Experimental Radiation Modalities for Malignant Astrocytomas

  1990cites this paper
• Hypoxia in Solid Tumours and Normal Tissues: Clinical Implications

  1990cites this paper
• A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).

  1989cites this paper
• Hypoxic Cell Radiosensitizers

  1989cites this paper
• Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.

  1989cites this paper
• Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170).

  1989cites this paper
• Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: evidence of diffusion from urine.

  1989cites this paper
• Cancer Management in Man

  1989cites this paper
• Addition of misonidazole, etanidazole, or hyperthermia to treatment with fluosol-DA/carbogen/radiation.

  1989cites this paper
• Radiobiology: nil desperandum.

  1989cites this paper
• Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers.

  1989cites this paper
• A New, Potent 2‐Nitroimidazole Nucleoside Hypoxic Cell Radiosensitizer, RP170

  1989cites this paper
• Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells.

  1989cites this paper
• Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study.

  1989cites this paper
• Chemical modifiers of cancer treatment.

  1988cites this paper
• The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).

  1988cites this paper
• Clinical chemosensitization by misonidazole and related compounds: a critical evaluation.

  1988cites this paper
• The Radiation Therapy Oncology Group: an outline of clinical research activities.

  1988cites this paper
• A new look at radionuclides therapy in metastatic disease of bone (review and prospects).

  1988cites this paper
• Additivity of radiosensitization by the combination of SR 2508 (etanidazole) and Ro 03-8799 (pimonidazole) in a murine tumor system.

  1988cites this paper
• Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).

  1988cites this paper
• International Clinical Trials in Radiation Oncology. Chemical modifiers.

  1988cites this paper
• Hypoxic cell radiosensitizers: illusion or elusion?

  1988cites this paper
• Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity.

  1988cites this paper
• Uptake and additivity of the radiosensitizing effects of Ro 03-8799 and SR-2508 in mammalian cells in vitro.

  1987cites this paper
• Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.

  1987influential citation
• Sensitization by SR-2508 plus Ro 03-8799.

  1986cites this paper